Polypeptide having factor Xa inhibitory method of reducing blood

Details Polypeptide having factor Xa inhibitory method of reducing blood Polypeptide having factor Xa inhibitory method of reducing blood

1995-06-06

1999-01-26

Carlson, Karen C.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

514 12, 530300, 530350, A61K 3754, C07K 14815

Patent

active

058635343

ABSTRACT:
A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.

REFERENCES:
patent: 4588587 (1986-05-01), Gasic
patent: 4742004 (1988-05-01), Hartman et al.
patent: 4791100 (1988-12-01), Kramer et al.
patent: 4832849 (1989-05-01), Cardin
patent: 5114922 (1992-05-01), Maschler
patent: 5182113 (1993-01-01), Rigbi et al.
patent: 5403596 (1995-04-01), Rigbi et al.
Baskova et al., Chemical Abstracts, 106:60996w (1986) (Exhibit 10);.
Condra et al., "Isolation and Structural Characterization of a Potent Inhibitor of Coagulation Factor Xa from the Leech Haementeria ghilianil", Thrombosis and Homeostasis 61(3):437-441. (Exhibit 11);.
Ferrailo, Bobbe L. and Mohler, Marjorie A., "Goals and Analytical Methodologies for Protein Disposition Studies", Protein Pharmacokinetics and Metabolism; Plenum Press. New York, 1992. pp. 1-33. (Exhibit 12);.
Han et al., (1989) "Cloning and Expression of cDNA Encoding Antistasin, a Leech-Derived Protein Having Anti-Coagulant and Anti-Metastatic Properties", Gene 75:47-57 (Exhibit) 13);.
Gasic et al., Cancer Res. 43:1633-1636 (1983) (Exhibit 14);.
Gasic et al., Cancer Res. 44:5670-5676 (1984) (Exhibit 15);.
Gasic et al., Chemical Abstracts 110:185955w (1986) (Exhibit 16);.
Hoffman et al., (1992) "Site-Directed Mutagenesis of the Leech-Derived Factor Xa Inhibitor Antistasin", Journ. Biol. Chem., 287:943-949 (Exhibit 17);.
Hopp et al., (1988) "A Short Polypeptide Marker Sequence Useful For Recombinant Protein Identification and Purification",.
Bio/technology 6:1204-1210 (Exhibit 18);.
Konrad, Michael W., (1993) "The Immune System as a Barrier to Delivery of Protein Theraputics", Biological Barriers to Protein Delivery, Plenum Press, New York, pp. 409-437. (Exhibit 19);.
Nutt et al., (1988) "The Amino Acid Sequence of Antistasin",.
Journ. Biol. Chem. 263(21):10162-10164 (Exhibit 20);.
Rigbi et al., (1990) Chemical Abstracts, 113:46259w (Exhibit 21);.
Tuszynski et al., (1987) "Isolation and Characterization of Antistasin", 262(20):9718-9723 (Exhibit 22);.
Dunwiddie et al., (1989), J. Biol. Chem. 264(28):16694-16699 (Exhibit 24);.
Sollner et al., Eur. J. Biochem. 219:937-943 (Exhibit 25).

Affiliated with

Also associated with

Rating

Polypeptide having factor Xa inhibitory method of reducing blood does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptide having factor Xa inhibitory method of reducing blood, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide having factor Xa inhibitory method of reducing blood will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1448008